Compare NSSC & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | VERA |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 3.0B |
| IPO Year | 1994 | 2021 |
| Metric | NSSC | VERA |
|---|---|---|
| Price | $36.19 | $31.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $50.67 | ★ $77.50 |
| AVG Volume (30 Days) | 259.3K | ★ 2.0M |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 0.84 | N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $202,316,000.00 | N/A |
| Revenue This Year | $8.29 | N/A |
| Revenue Next Year | $8.54 | $792.38 |
| P/E Ratio | $29.61 | ★ N/A |
| Revenue Growth | ★ 11.39 | N/A |
| 52 Week Low | $33.91 | $23.05 |
| 52 Week High | $51.77 | $56.05 |
| Indicator | NSSC | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 42.62 | 44.33 |
| Support Level | $35.22 | $30.05 |
| Resistance Level | $37.10 | $33.09 |
| Average True Range (ATR) | 0.78 | 2.06 |
| MACD | 0.00 | -0.22 |
| Stochastic Oscillator | 36.63 | 18.49 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.